Can-Fite BioPharma Ltd. Annual Report: A Simple Breakdown

I’ve put together this guide to help you understand how Can-Fite BioPharma performed this year. My goal is to turn complex filings into clear information so you can decide if this company fits your investment goals.

1. What does this company do?

Can-Fite is an Israeli biotech firm that develops "small-molecule" drugs targeting the A3 adenosine receptor. Their main projects include Piclidenoson for arthritis and psoriasis, Namodenoson for liver conditions, and CF602 for erectile dysfunction.

They are a research firm, not a manufacturer. They don't sell products yet; instead, they license their technology to partners like Ewopharma and Gebro Holding, who handle distribution once regulators approve the drugs.

2. Financial Performance

Can-Fite is in "investment mode," meaning they spend heavily on research while earning very little. For the year ending December 31, 2025, they brought in about $0.5 million, mostly from licensing fees.

Operating costs hit $12.4 million, largely due to clinical trials, resulting in a loss of about $11.9 million. Because they aren't selling products, they rely on occasional licensing payments and selling stock to fund their operations.

3. Major Wins and Challenges

• The Win: They advanced their Phase III study for Piclidenoson and received milestone payments from European partners, which validates their drug platform.
• The Challenge: Phase III trials are expensive, often costing tens of millions. These costs far exceed their current income, creating a cycle where the company must frequently raise money by selling more stock.

4. Financial Health & Recent Changes

The company is currently burning through cash, with about $4.2 million in the bank at the end of 2025.

• Share Count: As of December 31, 2025, they had 2,618,425 shares outstanding.
• The Reverse Split: On January 2, 2026, the company performed a 1-for-3,000 reverse stock split. This helped them meet the NYSE American’s $1.00 minimum price requirement. While this increased the price per share and lowered the total number of shares, it did not change the company’s underlying value.

5. Key Risks

• Dilution: To cover their $10M+ annual costs, the company frequently issues new shares. This reduces the percentage of the company owned by existing shareholders.
• Regulatory Hurdles: The company’s value depends entirely on FDA and EMA approval. If a major trial fails, the company could lose most of its value.
• Geopolitical Risk: Being based in Israel, the company faces risks from regional instability, which could disrupt lab work, clinical trials, or the ability to attract investors.
• Listing Requirements: The company has struggled to keep its stock price above $1.00. If they fail to meet exchange rules, they could be delisted, which would make it significantly harder to trade the stock.

6. Future Outlook

The company’s future depends on its upcoming clinical trial results. Keep a close eye on their "cash runway"—how long they can operate before needing more money. With $4.2 million in cash and high annual costs, they will likely need to raise more capital within 6 to 12 months unless they sign a major new deal.

Investment Tip: Before investing, ask yourself if you are comfortable with the high-risk nature of biotech research. Success in these trials is the only way this company moves from a cash-burning research firm to a profitable business. If you decide to move forward, monitor their news releases for any updates on trial results or new licensing agreements, as these are the primary catalysts for the stock price.